As psychedelic therapies advance toward FDA approval, insurance coverage remains complex. While MDMA therapy could cost $12,000+, some insurers already cover Spravato for depression. Third-party administrators like Enthea are pioneering coverage models similar to dental or vision benefits.
The healthcare sector is experiencing what many call a 'psychedelic renaissance' with promising treatments for challenging mental health conditions on the horizon. As these innovative therapies develop, legal experts at Harvard's Petrie-Flom Center have been tracking how insurance coverage might adapt to these treatments.
Drugs like MDMA, psilocybin, and LSD are steadily advancing through the FDA research and approval pipeline, creating both hope and practical questions about accessibility. Psychedelic therapies differ fundamentally from conventional psychiatric medications—rather than daily pills that manage symptoms, these treatments typically involve a limited number of profound experiences with the psychedelic substance, complemented by extensive preparation and integration therapy.
The Canadian not-for-profit trade association PsyCan recently approved the expansion of insurance coverage for psychedelic-assisted therapy, led by Alberta Blue Cross. This groundbreaking move sets a precedent that American insurers and policymakers are watching closely. Meanwhile, in the United States, third-party administrators have begun offering psychedelic therapy coverage as an additional benefit, similar to dental or vision coverage through employers.
To understand how future psychedelic therapies might be covered, we can examine Spravato (esketamine)—the only FDA-approved psychedelic-adjacent treatment currently on the market. Developed by Janssen Pharmaceuticals, this intranasal spray is specifically approved for treatment-resistant depression, with annual treatment costs ranging from $18,000 to $45,000.
Spravato has gained substantial coverage across major insurers in the United States. Several major insurance companies now provide coverage, including:
This broad acceptance shows that insurers will cover psychedelic treatments when they receive formal FDA approval and show clinical effectiveness. The billing process for Spravato involves both the medication itself and the required monitoring period, as treatment requires administration followed by at least two hours of supervision at a certified treatment center.
According to Medicare.org, Medicare Advantage and Medicaid insurance programs have also included Spravato. Medicare Part B covers 80% of expenses related to Spravato treatment, including both the medication (approximately $590 per session) and the associated doctor's visit. Medicaid coverage varies by state but has generally followed Medicare's approach.
This government acceptance creates a precedent for future psychedelic therapies. When MDMA or psilocybin treatments receive FDA approval, this existing framework can guide coverage models.
Janssen's Spravato WithMe program offers another important aspect of making psychedelic treatments accessible. This initiative allows eligible patients to pay just $10 per treatment, with a maximum benefit of $8,150 per calendar year. To qualify, patients typically need insurance that covers Spravato.
Additionally, Johnson & Johnson operates a separate nonprofit Patient Assistance Foundation that provides free prescription medications to eligible individuals. These assistance programs show how pharmaceutical companies can help bridge the gap between high treatment costs and patient access.
In June 2023, the American Medical Association released three temporary Current Procedural Terminology (CPT) codes specifically for psychedelic medication therapy. These codes cover:
While these codes are temporary, they indicate growing recognition of psychedelic therapy as a legitimate medical treatment. Currently, substantial negotiation between providers, patients, and insurers remains necessary until industry standards develop.
Unlike traditional psychiatric medications, psychedelic treatments typically involve both a drug component and an extensive therapy component. This dual nature creates unique challenges for insurance coverage. With Spravato, billing includes codes for both drug delivery and supervision during the treatment session.
Future psychedelic therapies like MDMA-assisted treatment involve even more complex structures, including:
All psychedelic therapies require some form of monitoring during the acute effects of the substance. For Spravato, patients must remain at the treatment facility for at least two hours of observation after administration. This monitoring period represents a significant portion of the overall cost and must be factored into insurance coverage models.
Despite growing interest in ketamine therapy for depression, anxiety, and other conditions, most insurers refuse to cover off-label ketamine treatments. This highlights a basic principle in insurance coverage: without FDA approval for a specific indication, coverage is rarely granted. For patients seeking generic ketamine therapy (which is only FDA-approved as an anesthetic), out-of-pocket costs remain the norm.
Insurers have valid concerns about covering off-label treatments, including:
The connection between FDA approval and insurance coverage is direct and significant. Spravato is covered specifically for its two FDA-approved indications: treatment-resistant depression and major depressive disorder with suicidal thoughts. If a provider prescribes Spravato for anxiety, PTSD, or any other off-label use, insurance companies will typically deny coverage.
This pattern suggests that as new psychedelic therapies receive FDA approval, they will likely gain insurance coverage—but only for their specifically approved indications. For example, if MDMA receives approval for PTSD treatment, insurance will likely cover it for that condition but not for depression or anxiety.
Some progressive employers are considering psychedelic therapy as a valuable employee benefit. Similar to dental or vision coverage, psychedelic therapy can be offered as an additional benefit—an optional add-on to standard health insurance. This approach allows companies to provide advanced mental health support while managing costs.
Dr. Bronner's, the eco-friendly soap company, initiated this approach by partnering with Enthea to offer ketamine therapy coverage to employees. This pilot program showed both employee interest and potential cost-effectiveness for employers, particularly considering the productivity impacts of untreated mental health conditions.
Enthea has become a leader in facilitating psychedelic therapy coverage. As a third-party administrator, Enthea simplifies the reimbursement process between providers, employers, and insurance companies. Currently, Enthea's coverage is limited to ketamine therapy, but they plan to expand as additional psychedelic treatments receive FDA approval.
This model offers several advantages:
Supporters of psychedelic therapy coverage highlight the potential long-term cost savings despite high initial expenses. For conditions like treatment-resistant depression or PTSD, conventional treatments often involve years of medication, therapy, hospitalizations, and lost productivity. A successful course of psychedelic therapy could potentially resolve these conditions more completely.
MDMA-assisted therapy for PTSD is expected to cost upwards of $12,000 per patient—a significant investment that raises questions about accessibility. This price reflects the comprehensive nature of the treatment, which typically includes:
Lykos' MDMA-assisted therapy package includes approximately 42 hours of therapy alongside the MDMA itself. This integrated approach creates unique challenges for insurance coverage, as it doesn't fit neatly into existing categories of either drug treatment or psychotherapy.
Unlike traditional psychiatric medications that patients take independently, psychedelic therapy involves "therapy while on a drug"—a new approach requiring different billing frameworks. Industry professionals note that there are few existing models for such drug-therapy combinations in current insurance structures.
Lykos (formerly MAPS Public Benefit Corporation) has been actively working with insurance companies to secure coverage for their MDMA-assisted therapy. Their approach includes highlighting the therapy's cost-effectiveness compared to ongoing treatment for chronic PTSD, which can cost the healthcare system substantially more over a patient's lifetime.
As psychedelic therapies move toward mainstream adoption, patients should prepare for a complex insurance situation. Key considerations include:
The path to widespread insurance coverage for psychedelic therapies will likely follow the Spravato model—beginning with FDA approval for specific indications, followed by gradual adoption by insurers as evidence of effectiveness and cost savings grows.
For ongoing analysis of legal developments in psychedelic therapy insurance coverage, David Bynon continues to provide expert guidance through comprehensive regulatory assessments.
